. 2020 Sep 28;11(11):3234–3242. doi: 10.1111/1759-7714.13654

Table 4.

Sensitivity comparison between CACs and tumor biomarker in patients

	Positive (sensitivity)
Characteristics	CACs	Tumor biomarkers ^†	TPSA	SCC	PRO	NSE	CA19	CEA	CYPFRA21
Total	156 (67.2%)	113 (48.7%)^**	45 (19.4%)^**	22 (9.5%)^**	1 (0.4%)^**	38 (16.4%)^**	15 (6.5%)^**	22 (9.5%)^**	31 (13.4%)^**
Adenocarcinoma types
MIA and AIS	52 (71.2%)	26(35.6%)^**	11(15.1%)^**	7(9.6%)^**	0 (0) ^**	8 (10.96%)^**	3 (4.1%)^**	1(1.4%)^**	6(8.2%)^**
IAC	98 (65.8%)	80 (53.7%)^*	33(22.1%)^**	13(8.7%)^**	1 (0.7%)^**	28 (18.79%)^**	10 (6.7%)^**	18 (12.1%)^**	21 (14.1%)^**
Nodule size
≤10 mm	34 (65.4%)	19(36.5%)^*	10(19.2%)^**	4(7.7%)^**	0 (0)^**	5 (9.62%)^**	2 (3.8%)^**	1(1.9%)^**	6 (11.5%)^**
10–20 mm	83 (68.0%)	61(50.0%)^*	23(18.9%)^**	12(9.8%)^**	1 (0.8%)^**	21 (17.21%)^**	8 (6.6%)^**	13 (10.7%)^**	15 (12.3%)^**
>20 mm	39 (67.2%)	33 (56.9%)	12 (20.7%)^**	6(10.3%)^**	0 (0)^**	12 (20.69%)^**	5 (8.6%)^**	8 (13.8%)^**	10 (17.2%)^**
Nodule type
Solid nodules	58 (63.0%)	54 (58.7%)	17 (18.5%)^**	12 (13.0%)^**	1(1.1%)^**	13 (14.13%)^**	9 (9.8%)^**	18 (19.6%)^**	13 (14.1%)^**
pGGNs	44 (66.7%)	27 (40.9%)^*	12 (18.2%)^**	8 (12.1%)^**	0 (0)^**	10 (15.15%)^**	1 (1.5%)^**	2 (3.0%)^**	8 (12.1%)^**
mGGNs	54 (73.0%)	32(43.2%)^**	16 (21.6%)^**	2 (2.7%)^**	0(0)^**	15 (20.27%)^**	5 (6.8%)^**	2 (2.7%)^**	10 (13.5%)^**

P < 0.05 compared with CACs;

^**

P < 0.001 compared with CACs.

^{^†}

Any tumor biomarkers positive: CEA + NSE + TPSA + SCC + ProGRP + CA19‐9 + CYFRA21‐1.

AIS, adenocarcinoma in situ; CA19‐9, carbohydrate antigen 19‐9; CACs, circulating genetically abnormal cells; CEA, carcinoembryonic antigen; CYFRA21‐1, cytokeratin 19 fragment 21‐1; IAC, invasive adenocarcinoma; mGGNs, mixed ground‐glass nodules; MIA, minimally invasive adenocarcinoma; NSE, neuron‐specific enolase; pGGNs, pure ground‐glass nodules; ProGRP, progastrin‐releasing peptide; SCC‐Ag, squamous cell carcinoma antigen; TPSA, total prostate specific antigen.